Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/05/052756
CTRI/2023/05/052756
Not yet recruiting
Phase 2

A randomized, open-label, phase II study to evaluate the efficacy and safety of a novel dose-dense regimen of docetaxel-cyclophosphamide alternating with epirubicin-cisplatin compared to standard dose-dense anthracycline, taxane and cyclophosphamide as neoadjuvant chemotherapy in early and locally advanced TNBC. - NeoPlaNET

CMC Vellore0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
CMC Vellore
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
CMC Vellore

Eligibility Criteria

Inclusion Criteria

  • •Documented histologically confirmed invasive ductal carcinoma of the breast
  • •ECOG Performance Status 0\-2
  • •Hormone Receptor Status should be documented as negative
  • •HER2 documented negative
  • •Stage I\-IIIC

Exclusion Criteria

  • •Pregnant, breastfeeding
  • •Multicentric or bilateral disease
  • •neuropathy grade 2 or above
  • •CCF NYHA class 3 or above
  • •LV dysfunction
  • •creatinine clearance less than 60 ml

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 2
A study to evaluate preventive treatments for talquetamab-related oral toxicityMultiple myelomaCancer
ISRCTN72589181Janssen-Cilag International NV120
Active, not recruiting
Phase 1
Study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome in adult severely ill patients with COVID-19.
EUCTR2020-001618-39-ESOryzon Genomics S. A.40
Active, not recruiting
Phase 1
A phase II, randomised, open-label study to evaluate the safety and immunogenicity of the adjuvanted pandemic H1N1 influenza candidate vaccine following a 0-28 day or 0-4 month vaccination schedule in subjects aged 8 to 12 weeks. - FLU D-PAN H1N1-012Immunisation against A/California/7/2009 (H1N1)v-like influenza in male and female children aged 8 to 12 weeks.
EUCTR2009-015174-35-NOGlaxoSmithKline Biologicals
Active, not recruiting
Not Applicable
A randomized, open-label phase II. study evaluating the efficacy and safety of FOLFOX6+Cetuximab versus FOLFIRI+Cetuximab as first line therapy in patients with metastatic colorectal cancerfirst line therapy in patients with metastatic cancer
EUCTR2004-002391-42-CZCECOG (Central European Cooperative Oncology Group)150
Active, not recruiting
Phase 1
M6620 in Combination with Avelumab and Carboplatin versus standard chemotherapy in Subjects with PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10038977Term: Retroperitoneal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-001534-17-GBMerck KGaA90